(Date:11/20/2008)...umption of illicit or noncommercial alcohol is wid...s significantly to the global burden of disease, a...ernational Center for Alcohol Policies (ICAP). The...l, defined as traditional beverages produced for h...feit or unregistered products, in three regions: s...
(Date:11/20/2008)... results in review of national program , ...l cancer screening detects 40 percent of cancers a...e, say Finnish Cancer Registry researchers. , T...rmine how sensitive Finland,s colorectal cancer sc...sease. Half the people were assigned to a screenin...
(Date:11/20/2008)...spiratory disease , , THURSDAY, Nov. 20 ...ng ovulation may explain why women with cystic fib...tory disease, researchers at the University of Nor..., published in the Nov. 20 issue of the Journal o... reduce estrogen levels, such as tamoxifen, might ...
(Date:11/20/2008)... The National Minority Quality Forum (NMQF) today ...t decision to develop a Health Insurer Code of Con... to join the Forum in encouraging adoption and com...sicians and lawyers -- even politicians -- follow ...nt and Chief Executive Officer of the Forum. "It,s...
Breaking Medicine News(10 mins):Health News:Report finds extensive use of illicit alcohol 2Health News:Colorectal Cancer Screens Detect Unrecognized Disease 2Health News:Estrogen May Explain Why Women With Cystic Fibrosis Suffer More 2Health News:Estrogen May Explain Why Women With Cystic Fibrosis Suffer More 3Health News:National Minority Quality Forum Applauds AMA's Health Insurer Code of Conduct 2(Date:11/19/2008)...tCall/ -- Amgen,(Nasdaq: AMGN ) and Millennium:...eda Pharmaceutical Company Limited (TSE: 4052), to...T1 trial evaluating motesanib (AMG 706) in,combin...t-line treatment of,advanced non-small cell lung ...lowing a planned safety data review of 600 patient...
(Date:11/19/2008)...itical enzyme,s regulation may hold key to underst..., , MEMPHIS, Tenn., Nov. 19 /PRNewswire-USNe...arch Hospital have gained new insights into regula... calpains. , , As the cell,s molecular ove...cesses, including the movement of cells in tissues...
(Date:11/19/2008)... contract development and,manufacturing organizat...,phase launch of its contract facility in Delawar... process, facility and capacity problems commonly,...-volume clinical and,early-stage commercial steri...invest over $100 million and four years to develop...
(Date:11/18/2008)...euroDiscovery Ltd (ASX:,NDL), a specialty neurosc...y,and Sosei Group Corporation ("Sosei"; TSE Moth...maceutical company, today announce that NeuroSolut...fficacy data for NSL-043/SD118.,This investigatio...in and has,successfully completed Phase I clinica...
Breaking Medicine Technology:Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3Isogen Launches Major New Facility to Address Global Biopharma Demand 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 3World Leader in Bench Top Flow Chemistry Instruments ThalesNano Inc Introduces an Industry First Seminar Series 7904 1World Leader in Bench Top Flow Chemistry Instruments ThalesNano Inc Introduces an Industry First Seminar Series 7904 2Alzheimers Foundation of America Encourages Global Action on Awareness Raising 26759 1Alzheimers Foundation of America Encourages Global Action on Awareness Raising 26759 227 National Nursing Organizations Join Together to Commission a Study of the Impact of Advanced Practice Registered Nurses on Healthcare Quality Safe 26751 127 National Nursing Organizations Join Together to Commission a Study of the Impact of Advanced Practice Registered Nurses on Healthcare Quality Safe 26751 227 National Nursing Organizations Join Together to Commission a Study of the Impact of Advanced Practice Registered Nurses on Healthcare Quality Safe 26751 3CU Boulder study suggests air quality regulations miss key pollutants 5058 1CU Boulder study suggests air quality regulations miss key pollutants 5058 2...OS ANGELES, April 17, 2007 /PRNewswire/ -- Researc...e in Detroit, MI presented,strong evidence today t...er,s patients could be effective in eventually tre...D., leader, Prevention Program at Karmanos, and,me...tudy showing,that the drug Clioquinol (CQ) appears...
...econd generation,pyridopyrazine-urea derivative ...ition which could be valuable for cancer,treatme...terna Zentaris Inc. (TSX: AEZ; Nasdaq:,AEZS), a ...d on,endocrine therapy and oncology, today prese...n its pyridopyrazine derivatives,with high selec...
Other Medicine Technology:Alzheimer's Drug Shows Promise in Fighting Cancer 2terna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 2terna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 3terna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 4...has a sharp linear blade and a spring-loaded locki...ade; PLUS V2 trocar is available in 5 mm, 5 mm-11 ...diolucent sleeve and shield. The VERSAPORT™ ...ng-loaded locking shield. Upon entry into a free s...
...rade; single use nonconductive anchoring devices a... for use with the SURGIPORT™ radiolucent tro...and 10 mm-15 mm sizes for use with the VERSAPORT&t..., SURGIPORT™ III and VISIPORT™ radiolu...
... ...unlike any trocar system you've ever seen., ,...systems in one designed to be versatile, operatio...our needs., ,By offering options in disposability... can effectively address the individual preference...
... ...unlike any trocar system you've ever seen., ,...systems in one designed to be versatile, operatio...our needs., ,By offering options in disposability... can effectively address the individual preference...
Medicine Products: